Edgewise Therapeutics (EWTX) Cash from Investing Activities (2020 - 2026)

Edgewise Therapeutics has disclosed Cash from Investing Activities across 7 years of filings, most recently posting $2.4 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $2.4 million, down 94.46% year-over-year; the trailing twelve-month figure through Mar 2026 was -$74.3 million (down 158.22% YoY), and the FY2025 annual result was -$32.8 million, up 82.24% from the prior year.
• Cash from Investing Activities came in at $2.4 million for Q1 2026 at Edgewise Therapeutics, down from $49.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $49.8 million in Q4 2025 to a low of -$268.3 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $23.4 million (2023), against an average of -$10.7 million.
• Across the five-year window, Cash from Investing Activities soared 7582.61% in 2023 and plunged 647.1% in 2024, its largest moves.
• Edgewise Therapeutics' Cash from Investing Activities stood at -$75.6 million in 2022, then jumped by 135.69% to $27.0 million in 2023, then decreased by 22.46% to $20.9 million in 2024, then jumped by 137.85% to $49.8 million in 2025, then slumped by 95.11% to $2.4 million in 2026.
• The last three Cash from Investing Activities figures came in at $2.4 million (Q1 2026), $49.8 million (Q4 2025), and $35.7 million (Q3 2025), per Business Quant data.